Human TRANCE/TNFSF11/RANK L Antibody

Name: Human TRANCE/TNFSF11/RANK L Antibody
Brand: R&D Systems
SKU: MAB626-100
Rating: 4.5 (2 reviews)

Catalog #: MAB626
9 Citations 2 Reviews Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB626-SP
MAB626-500
MAB626-100

Osteoclast-Like Cell Formation Induced by TRANCE/TNFSF11/RANK L and Neutralization by Human TRANCE/TNFSF11/RANK L Antibody.

2 Images

View All Products for TRANCE/TNFSF11/RANK L

Product Details

Citations (9)

FAQs

Supplemental Products

Reviews (2)

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human TRANCE/TNFSF11/RANK L Antibody Summary

Species Reactivity

Human

Specificity

Detects human TRANCE/TNFSF11/RANK L in direct ELISAs. No cross-reactivity with recombinant mouse TRANCE is observed.

Source

Monoclonal Mouse IgG_2B Clone # 70525

Purification

Protein A or G purified from ascites

Immunogen

S. frugiperda insect ovarian cell line Sf 21-derived recombinant human TRANCE/TNFSF11/RANK L
Gly136-Asp317 (Ala194Gly)
Accession # O14788

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Immunohistochemistry

8-25 µg/mL

See below

Neutralization

Measured by its ability to neutralize TRANCE/TNFSF11/RANK L-induced osteoclast-like cell formation in RAW 264.7 mouse macrophages. The Neutralization Dose (ND₅₀) is typically 0.8-2.5 µg/mL in the presence of 30 ng/mL Recombinant Human TRANCE/TNFSF11/RANK L.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

Osteoclast-Like Cell Formation Induced by TRANCE/TNFSF11/RANK L and Neutralization by Human TRANCE/TNFSF11/RANK L Antibody. In the presence of Recombinant Mouse M-CSF (20 ng/mL, Catalog # 416-ML), Recombinant Human TRANCE/TNFSF11/RANK L (Catalog # 390-TN) induces osteoclast-like cell formation in RAW 264.7 mouse macrophages in a dose-dependent manner (orange line), as measured by TRAP (tartrate-resistant acid phosphatase) activity in cell lysates. Under these conditions, osteoclast-like cell formation elicited by Recombinant Human TRANCE/ TNFSF11/RANK L (30 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human TRANCE/TNFSF11/RANK L Monoclonal Antibody (Catalog # MAB626). The ND₅₀ is typically 0.8-2.5 µg/mL.

Immunohistochemistry

View Larger

TRANCE/TNFSF11/RANK L in Human Lymph Node. TRANCE/TNFSF11/RANK L was detected in immersion fixed paraffin-embedded sections of human lymph node using 5 µg/mL Mouse Anti-Human TRANCE/TNFSF11/RANK L Monoclonal Antibody (Catalog # MAB626) overnight at 4 °C. Tissue was stained with the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Reconstitution Buffer Available

Reconstitution Buffer 1 (PBS)

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TRANCE/TNFSF11/RANK L

TNF-related activation-induced cytokine (TRANCE; also RANKL, OPGL, and ODF) is a 35 kDa (predicted) type II transmembrane glycoprotein and member of the TNF cytokine family. Human TRANCE is 317 amino acids (aa) in length and contains a 47 aa cytoplasmic region, a 21 aa transmembrane region, and a 249 extracellular domain (ECD), which contains two potential sites of N-linked glycosylation. Splicing variants produce three isoforms for human TRANCE. Isoform 1 is the standard form. In isoform 2 lacks aa 1-73, and isoform 3 lacks aa 1-47. TRANCE is expressed highest in the peripheral lymph nodes and weaker in the spleen, peripheral blood leukocytes, bone marrow, heart,placenta, skeletal muscle, stomach, and thyroid. TRANCE plays a role in osteoclast differentiation and activation.

Long Name

TNF-related Activation-induced Cytokine

Entrez Gene IDs

8600 (Human); 21943 (Mouse); 117516 (Rat); 102137946 (Cynomolgus Monkey)

Alternate Names

CD254 antigen; CD254; ODF; OPGL; OPGLOPTB2; Osteoclast differentiation factor; Osteoprotegerin ligand; RANK L; RANKL; RANKLreceptor activator of nuclear factor kappa B ligand; Receptor activator of nuclear factor kappa-B ligand; sOdf; TNF-related activation-induced cytokine; TNFSF11; TRANCE; TRANCEODFhRANKL2; tumor necrosis factor (ligand) superfamily, member 11; tumor necrosis factor ligand superfamily member 11

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Human TRANCE/TNFSF11/RANK L Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

9 Citations: Showing 1 - 9
Filter your results:

Filter by:

Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer
Authors: I Gomes, BP de Almeida, S Dâmaso, A Mansinho, I Correia, S Henriques, R Cruz-Duart, G Vilhais, P Félix, P Alves, P Corredeira, NL Barbosa-Mo, L Costa, S Casimiro
Oncotarget, 2020-05-12;11(19):1714-1728.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization
The Possible Role of Neutrophils in the Induction of Osteoclastogenesis
Authors: CGJ Moonen, TJ de Vries, P Rijkschroe, PE Poubelle, EA Nicu, BG Loos
J Immunol Res, 2019-09-15;2019(0):8672604.
Species: Human
Sample Types: Whole Cells
Applications: ICC
The effect of vascular endothelial growth factor on osteoclastogenesis in rheumatoid arthritis.
Authors: Kim H, Kim K, Kim B, Cho M, Lee S
PLoS ONE, 2015-04-20;10(4):e0124909.
Species: Human
Sample Types: Cell Culture Supernates
Applications: IHC
Proteinase-activated receptor (PAR)-2 activation impacts bone resorptive properties of human osteoarthritic subchondral bone osteoblasts.
Authors: Amiable N, Tat SK, Lajeunesse D, Duval N, Pelletier JP, Martel-Pelletier J, Boileau C
Bone, 2009-03-02;44(6):1143-50.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
alpha1beta1 integrin and interleukin-7 receptor up-regulate the expression of RANKL in human T cells and enhance their osteoclastogenic function.
Authors: Gendron S, Boisvert M, Chetoui N, Aoudjit F
Immunology, 2008-05-13;125(0):359.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot
A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies.
Authors: Lee N, Smolarz AJ, Olson S, David O, Reiser J, Kutner R, Daw NC, Prockop DJ, Horwitz EM, Gregory CA
Br. J. Cancer, 2007-11-06;97(11):1552-9.
Species: Human
Sample Types: Cell Lysates, Whole Tissue
Applications: IHC-P, Western Blot
Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis.
Authors: Makrygiannakis D, af Klint E, Catrina SB, Botusan IR, Klareskog E, Klareskog L, Ulfgren AK, Catrina AI
Arthritis Rheum., 2006-05-01;54(5):1463-72.
Species: Human
Sample Types: Cell Lysates, Whole Cells, Whole Tissue
Applications: Flow Cytometry, IHC, Western Blot
Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
Authors: Mandelin J, Li TF, Hukkanen M, Liljestrom M, Salo J, Santavirta S, Konttinen YT
J. Rheumatol., 2005-04-01;32(4):713-20.
Species: Human
Sample Types: Whole Tissue
Applications: IHC
Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome.
Authors: Fonseca JE, Cortez-Dias N, Francisco A, Sobral M, Canhao H, Resende C, Castelao W, Macieira C, Sequeira G, Saraiva F, da Silva JA, Carmo-Fonseca M, Viana Queiroz M
Clin. Exp. Rheumatol., 2005-03-01;23(2):185-92.
Species: Human
Sample Types: Whole Tissue
Applications: IHC